Introduction:
Leading pharmaceutical company has announced March 26, 2025, as the record date for its 1:20 bonus issue. This strategic move aims to enhance stock liquidity and reward shareholders, reinforcing the company’s commitment to long-term investor value and growth.
Share price movement of Beta Drugs:
On March 18, 2025, Beta Drugs Limited opened at ₹1,800.00, rising 2.29% from its previous close of ₹1,755.80. The stock hit a high of ₹1,804.95 and a low of ₹1,758.00. By 3:11 PM, it traded at ₹1,795.95, with a market cap of ₹1,726.60 crore.
Beta Drugs Sets Record Date for 1:20 Bonus Issue:
Beta Drugs Ltd. has announced March 26, 2025, as the record date for its 1:20 bonus issue. Shareholders holding fully paid-up equity shares of ₹10 each will receive one additional share for every 20 shares held, enhancing stock liquidity.
The company’s shareholders approved the bonus issue via a special resolution through postal ballot, as confirmed in its March 12, 2025 disclosure. The move aligns with Beta Drugs’ strategy to reward investors and boost shareholder value in the long term.
The deemed allotment date for the bonus shares is March 27, 2025. The initiative reflects the company’s commitment to strengthening investor confidence while maintaining robust financial performance. Investors can check further details on the company’s official website.
Recent news on Beta Drugs:
As of November 27, 2024, Beta Drugs, a vertically integrated oncology-focused company, raised ₹117 crore in primary capital from HealthQuad Fund II and other investors, including a Singapore-based investment fund and a private wealth management firm, for a minority stake.
Ace investor holding in Beta Drugs:
Ashish Kacholia
Ace investor Ashish Kacholia holds a 5.78% stake in Beta Drugs Ltd with 556,000 shares, valued at ₹99.9 crore. His investment highlights confidence in the company’s growth potential in the oncology-focused pharmaceutical sector.
Stock performance of Beta Drugs for Period of 1 week, 6 months, and 1 year:
Beta Drugs Ltd has delivered strong returns, gaining 3.89% in a week and 2.45% over six months. The stock has surged 37.3% in a year, reflecting investor confidence and the company’s robust growth in the oncology pharmaceutical sector.
Also Read: FMCG stock jumps after receiving CCI approval to acquire 90.5% stake in parent company of Minimalist
Shareholding pattern of Beta Drugs:
Particulars | Dec 2024 | Sep 2024 | Jun 2024 |
Promoter | 66.70% | 66.70% | 66.70% |
FII | 1.20% | 1.20% | 1.20% |
DII | 0.20% | 0.20% | 0.20% |
Public | 32% | 31.90% | 32.00% |
About Beta Drugs:
Beta Drugs Ltd (NSE: BETA) specializes in manufacturing a wide range of oncology (anti-cancer) drugs. With a strong presence in domestic and export markets, the company is committed to advancing cancer treatment through high-quality pharmaceutical formulations.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.